Maxion Therapeutics’ $16 million Series A financing round will be used to develop biologics targeting ion channels and GPCRs via its KnotBody platform. Cambridge, UK based firm Maxion said ion channels and G-protein-coupled receptors (GPCRs) are essential cell surface proteins, which can be used to treat a range of diseases, including chronic pain and autoimmune conditions. The Series A funding round, led by LifeArc Ventures, BGF, and Monograph Capital, will support the advancement of Maxion’s KnotBody platform. To date, small…
